前列腺腺癌转化为神经内分泌肿瘤1例报道并文献复习

Abstract
Figure/Table
References (26)
Related Citation (15)

Download: PDF (701 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Neuroendocrine tumor of the prostate is a rare malignant tumor. In order to improve the understanding of neuroendocrine tumor of the prostate, this study retrospectively analyzed the data of one case of prostate adenocarcinoma transformed into neuroendocrine tumor of the prostate in Hubei Cancer Hospital. The clinical and pathological features, diagnosis, and treatment and prognosis of neuroendocrine tumor of the prostate were reviewed in combination with relevant literature. Neuroendocrine tumor of the prostate is rare, and some of them are prostate adenocarcinoma transformed into neuroendocrine tumor after androgen deprivation therapy. The diagnosis is based on clinical and pathological diagnosis. Neuroendocrine tumor of the prostate has a high degree of malignancy. The treatment is mainly chemotherapy, and the prognosis is poor.

Key words： Prostatic adenocarcinoma Neuroendocrine tumor of the prostate Androgen deprivation therapy Transformation

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	YIN Zhucheng LIANG Xinjun

Cite this article:

YIN Zhucheng LIANG Xinjun. A case report and literature review prostatic adenocarcinoma transformed into neuroendocrine tumor of the prostate[J]. 中国医药导报, 2022, 19(21): 185-188.

URL:

https://www.yiyaodaobao.com.cn/EN/ OR https://www.yiyaodaobao.com.cn/EN/Y2022/V19/I21/185

[1] Wang W，Epstein JI. Small cell carcinoma of the prostate：a morphologic and immunohistochemical study of 95 cases [J]. Am J Surg Pathol，2008，32（1）：65-71.
[2] Zong Y，Goldstein AS. Adaptation or selection-Mechanisms of castration-resistant prostate cancer [J]. Nature Reviews Urology，2013，10（2）：90-98.
[3] Aggarwal R，Huang J，Alumkal JJ，et al. Clinical and Genomic Characterization of Treatment-Emergent Small-Cell Neuroendocrine Prostate Cancer：A Multi-institutional Prospective Study [J]. J Clin Oncol，2018，36（24）：2492-2503.
[4] Abida W，Cyrta J，Heller G，et al. Genomic correlates of clinical outcome in advanced prostate cancer [J]. Proc Natl Acad Sci U S A，2019，116（23）：11428-11436.
[5] Wenk RE，Bhagavan BS，Levy R，et al. Ectopic ACTH，prostatic oat cell carcinoma，and marked hypernatremia [J]. Cancer，1977，40（2）：773-778.
[6] Zhang Y，Ouyang W，Sun G，et al． Pure small cell carcinoma of the prostate：A report of 8 cases [J]. Urol Int，2018，101（ 3）：263-268．
[7] Petraki C，Vaslamatzis M，Petraki K，et al． Prostate cancer with small-cell morphology：An immunophenotypic subdivision [J]. Scand J Urol Nephrol，2005，39（6）：455-463.
[8] Beltran H，Rickman DS，Park K，et al. Molecula characterization of neuroendocrine prostate cancer and identification of new drug targets [J]. Cancer Discov，2011，1（6）：487-495.
[9] Mosquera JM，Beltran H，Park K，et al. Concurrent AURKA and MYCN gene amplifications are harbingers of lethal treatment-related neuroendocrine prostate cancer [J]. Neoplasia，2013，15（1）：1-10.
[10] Wang J，Liu X，Wang Y，et al. Current trend of worsening prognosis of prostate small cell carcinoma：A population-based study [J]. Cancer Med，2019，8（15）：6799-6806.
[11] Usmani S，Orevi M，Stefanelli A，et al. Neuroendocrine differentiation in castration resistant prostate cancer. Nuclear medicine radiopharmaceuticals and imaging techniques：A narrative review [J]. Crit Rev Oncol Hematol，2019，138：29-37.
[12] Parghane R，Basu S. Small Cell Transformation of Metastatic Prostate Adenocarcinoma Diagnosed by Dual-Tracer PET/CT（68 Ga-PSMA and 18 F-FDG）：Potential Clinical Utility in Therapeutic Decision Making and Treatment Monitoring [J]. J Nucl Med Technol，2019，47（1）：85-87.
[13] 潘立立，吴小艾，刁伟，等．正电子核素标记的前列腺特异性膜抗原小分子抑制剂在前列腺癌PET/CT中的研究进展[J].生物医学工程学杂志，2020，37（2）：219-224.
[14] Yao JL，Madeb R，Bourne P，et al. Small cell carcinoma of the prostate：an immunohistochemical study [J]. Am J Surg Pathol，2006，30（6）：705-712.
[15] 范晋海，王磊，南勋义，等．前列腺小细胞癌诊治再分析[J].中华泌尿外科杂志，2011，32（9）：591-594．
[16] Nadal R，Schweizer M，Kryvenko ON，et al. Small cell carcinoma of the prostate [J]. Nat Rev Urol，2014，11（4）：213-219.
[17] Liu B，Li L，Yang G，et al. PARP Inhibition Suppresses GR-MYCN-CDK5-RB1-E2F1 Signaling and Neuroendocrine Differentiation in Castration-Resistant Prostate Cancer [J]. Clin Cancer Res，2019，25（22）：6839-6851.
[18] Puca L，Gavyert K，Sailer V，et al. Delta-like protein 3 expression and therapeutic targeting in neuroendocrine prostate cancer [J]. Sci Transl Med，2019，11（484）：eaav0891.
[19] Horn L，Mansfield AS，Szczesna A，et al. First-line atezolizumab plus chemotherapy in extensive-stage small-cell lung cancer [J]. N Engl J Med，2018，379（23）：2220-2229．
[20] Liu SV，Reck M，Mansfield AS，et al. Updated Overall Survival and PD-L1 Subgroup Analysis of Patients With Extensive-Stage Small-Cell Lung Cancer Treated With Atezolizumab，Carboplatin，and Etoposide （IMpower133）[J]. J Clin Oncol，2021，39（6）：619-630.
[21] Wee CE，Costello BA，Orme JJ，et al. Chemotherapy with atezolizumab for small cell or neuroendocrine carcinoma of the prostate：A single institution experience [J]. Prostate，2021，81（13）：938-943.
[22] Wang HT，Yao YH，Li BG，et al. Neuroendocrine prostate cancer （ NEPC） progressing from conventional prostatic adenocarcinoma：Factors associated with time to development of NEPC and survival from NEPC diagnosis-a systematic review and pooled analysis [J]. J Clin Oncol，2014，32（30）：3383-3390.
[23] 张敏，史伟，张其伟，等.前列腺小细胞神经内分泌癌诊疗特点分析[J].中华男科学杂志，2021，27（3）：219-225.
[24] 何岩，吴春磊，李泽宇，等.前列腺小细胞癌5例报告并文献复习[J].现代泌尿外科杂志，2021，26（5）：391-394.
[25] Vincenza C，Oromendia C，Eng KW，et al. Clinical features of neuroendocrine prostate cancer [J]. Eur J Cancer，2019，121：7-18.
[26] Bell PD，Huber AR，Agostini-Vulaj D. Clinicopathologic features of metastatic small cell carcinoma of the prostate to the liver：a series of four cases [J]. Diagn Pathol，2021， 16（1）：35.